Date: 2012-02-29
Type of information: Licensing agreement
Compound: phosphodiesterase (PDE) platform including PDE2 inhibitors and BCA909
Company: biocrea (Germany) Boehringer Ingelheim (Germany)
Therapeutic area: undisclosed
Type agreement: licensing
asset purchase
Action mechanism:
Disease: undisclosed
Details: biocrea has announced the completion of an asset purchase and licensing deal with Boehringer Ingelheim. Under the terms of the agreement, biocrea will receive an undisclosed payment and will transfer the exclusive global rights for certain research programs originating from its phosphodiesterase (PDE) platform to Boehringer Ingelheim. This includes biocrea´s PDE2 inhibitors and its most advanced compound BCA909.
The proceeds from this agreement will allow biocrea to implement its strategy to build a sustainable company over the next several years.
Financial terms:
Latest news:
